Centre Oscar Lambret (UNICANCER)

Research facility


Location: Lille, France (FR) FR

ISNI: 0000000101316312

ROR: https://ror.org/03xfq7a50

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study (2023) Turner NC, Laird AD, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, et al. Journal article Clinical Characteristics and Outcome of Children With Wagr Syndrome and Wilms Tumor Identified through SIOP-RTSG Registries (2020) Hol JA, Jongmans MCJ, Sudour-Bonnange H, Ramirez-Villar GL, Chowdhury T, Rechnitzer C, Pal N, et al. Conference contribution Clinical characteristics and outcomes of children with WAGR syndrome and Wilms tumor and/or nephroblastomatosis: The 30-year SIOP-RTSG experience (2020) Hol JA, Jongmans MCJ, Sudour-Bonnange H, Ramirez-Villar GL, Chowdhury T, Rechnitzer C, Pal N, et al. Journal article The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients (2020) Alman B, Attia S, Baumgarten C, Benson C, Blay JY, Bonvalot S, Breuing J, et al. Journal article, Review article Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations (2019) Turner NC, Laird AD, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, et al. Conference contribution A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO) (2019) Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, Mina LA, et al. Journal article Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial (2018) Hurvitz SA, Quek RGW, Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, et al. Journal article Salvage Mastectomy Versus Second Conservative Treatment for Second Ipsilateral Breast Tumor Event: A Propensity-Score Matched Cohort Analysis (2018) Levi JMH, Van Limbergen E, Gal J, Schiappa R, Polgar C, Kauer-Dorner D, Pasquier D, et al. Conference contribution An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG) (2017) Kasper B, Baumgarten C, Garcia J, Bonvalot S, Haas R, Haller F, Hohenberger P, et al. Journal article Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project+ (2015) Kramar A, Negrier S, Sylvester R, Joniau S, Mulders P, Powles T, Bex A, et al. Journal article